BLUE Overview
Upcoming Projects (BLUE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (BLUE)
-
Key Takeaways from ASH 2021: A conversation with a hematologist attending the conference
Tickers: SNY, IBB, BLUE, QURE
Executed On: Dec 13, 2021 at 02:30 PM EST
Expired Projects (BLUE)
-
Digging into Bluebird’s bb21217 P1 in treating Multiple Myeloma
Ticker: BLUE
Execute By: Mar 06, 2020
Upcoming & Overdue Catalysts (BLUE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (BLUE)
-
Bluebird Bio's(BLUE) Phase 3 data of LentiGlobin - HGB-212 Northstar-3 in TDT and the β0/β0genotype to be presented at EHA
Ticker: BLUE
Occurred on: Jun 14, 2019 -
Bluebird Bio (BLUE) to finish Phase 1/2 study of LentiGlobin® BB305 in Beta-Thalassemia Major Subjects in September 2017
Ticker: BLUE
Occurred on: Dec 10, 2017 -
Phase 1/2 trial updated data of LentiGlobin for β-Thalassemia and Sickle Disease expected at ASH December 2016
Ticker: BLUE
Occurred on: Dec 05, 2016 -
BlueBird Bio's (BLUE) LentiGlobin for Transfusion-Dependent Beta Thalassemia Granted PRIME Status by EMA
Ticker: BLUE
Occurred on: Sep 21, 2016 -
Bluebird Bio (BLUE) CFO to resign, replaced by COO
Ticker: BLUE
Occurred on: Mar 18, 2016
Strategic Initiatives (BLUE)
-
Bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy
Ticker: BLUE
Announcement Date: Dec 07, 2017